低分子肝素钠联合奥扎格雷钠治疗急性进展性脑梗死的疗效观察及安全性评价

The efficacy and safety evaluation of sodium low molecular weight heparin combined with sodium ozagrel in treatment of progressive cerebral infarction

目的观察低分子肝素钠与奥扎格雷钠联合治疗急性进展性脑梗死的疗效及安全性。方法将60例进展性脑梗死患者按1：1分成治疗组和对照组各30例。治疗组给予低分子肝素钠5000u，bid，脐周ih，奥扎格雷钠80mg，bid，静脉滴注；对照组给予奥扎格雷钠80mg，bid，疗程15d。观察两组患者治疗前后临床神经功能缺失程度评分、血小板聚集率的变化，并进行比较。结果治疗纽总有效率93．3％，明显高于对照组76．7％（P〈0．叭）。治疗组凝血酶元时间优于对照组（P〈0．05），两组血小板聚集率于治疗前后均有明显变化（P〈0．01）。结论低分子肝素钠合并奥扎格雷钠为治疗急性进展性脑梗死的安全、有效的治疗方法。

Objective To study the efficacy and safety of sodium low molecular weight heparin combined with sodium ozagrel in treatment of progressive cerebral infarction. Methods 60 cases of progressive cerebral infarction were divided into treatment group （ n = 30 ） and control group（ n = 30）. Patients in treatment group were treated with sodium low weight molecular hepafin （5000u bid ih） and sodium ozagrel（ 80mg bid ivgtt） . and patients in control group were treated with sodium ozagrel（ 80rag bid ivgtt） for 15 days. Clinical neural function deficit and platelet adhesive rate were compared between two groups before and after treatment. Results The total effective rate in treatment group （93. 3% ） was higher than that in control group（76.7% ） （P 〈 0.01 ）. prothrombin time （PT） in treatment group was better than that in control group（ P 〈0. 05 ）. and platelet adhesive rate in both groups were changed significantly. Conclusions Sodium low weight heparin combined with sodium ozagrel were safe and effective in treating progressive cerebral infarction.